arrow
S

Susana Roselló

incliva biomedical research institute
H指数:37
被引数:6,170

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Spatial Dynamics Links PD-L1 and Tumor-Associated Macrophage-Enriched Niches to Immune and Mesenchymal States in Microsatellite-Stable Colorectal Cancer

空间动力学将PD-L1与肿瘤相关巨噬细胞富集的微环境与免疫和间质状态联系起来,在微卫星稳定型结直肠癌中

Cancers
IF4.4
2026-04-180
OAAI
Clinical performance of tumor-informed versus tumor-agnostic ctDNA assays for colorectal cancer recurrence: A systematic review and diagnostic accuracy meta-analysis

基于肿瘤信息的循环肿瘤DNA检测与肿瘤无特异性循环肿瘤DNA检测在结直肠癌复发中的临床表现:一项系统评价和诊断准确性Meta分析

2025-12-070
OAAI
Efficacy and safety of atezolizumab plus bevacizumab in MSI-like metastatic colorectal cancer: a multicenter, single-arm, phase II, open-label clinical trial

阿特珠单抗联合贝伐珠单抗在MSI-like转移性结直肠癌中的有效性和安全性:一项多中心、单臂、II期、开放标签临床试验

2025-12-020
OAAI
A radiomics-based artificial intelligence model to assess the risk of relapse in localized colon cancer

一种基于放射组学的人工智能模型,用于评估局部结肠癌的复发风险

2025-07-160
OAAI
A randomized blinded phase II study of ompenaclid (RGX-202-01) vs placebo in combination with FOLFIRI plus bevacizumab (BEV) in patients (pts) with previously treated RAS mutated (RASmt) advanced/metastatic colorectal cancer (mCRC)

一项关于奥潘奈利(ompenaclid,RGX-202-01)与安慰剂在联合FOLFIRI方案加贝伐珠单抗(BEV)治疗既往接受过治疗的RAS突变(RASmt)晚期/转移性结直肠癌(mCRC)患者中的随机双盲II期研究

2024-09-010
PRE
Sequencing paired tumor DNA and white blood cells improves circulating tumor DNA tracking and detects pathogenic germline variants in localized colon cancer
2023-12-014
OAAI
Proteotranscriptomic analysis of advanced colorectal cancer patient derived organoids for drug sensitivity prediction

用于药物敏感性预测的晚期结直肠癌患者衍生的类器官的蛋白质转录组学分析

2023-01-0629
OAAI
Integrative immune transcriptomic classification improves patient selection for precision immunotherapy in advanced gastro-oesophageal adenocarcinoma
2022-10-173
OA
Epigenetic engineering on CDX2 allows to determine the interplaying consequences with other genetic and transcriptomic events in colorectal cancer
2022-09-010
OAAI
Clinicians' Attitude to Doublet Plus Anti-EGFR Versus Triplet Plus Bevacizumab as First-line Treatment in Left-Sided RAS and BRAF Wild-Type Metastatic Colorectal Cancer Patients: A Multicenter, Real-Life, Case-Control Study

在左侧RAS和BRAF野生型转移性结直肠癌患者中,临床医生对双联加抗EGFR与三联加贝伐单抗作为一线治疗的态度: 一项多中心,现实生活,病例对照研究

2021-12-017
PRE
Post-Induction Management in Patients With Left-Sided RAS and BRAF Wild-Type Metastatic Colorectal Cancer Treated With First-Line Anti-EGFR-Based Doublet Regimens: A Multicentre Study
2021-10-275
OAAI
Molecular profiling of advanced solid tumours. The impact of experimental molecular-matched therapies on cancer patient outcomes in early-phase trials: the MAST study
2021-09-0719
OAAI
Exome sequencing of ctDNA portrays the mutational landscape of patients with relapsing colon cancer and indicates new actionable targets
2021-09-011
OAAI
Retrospective Study of Regorafenib Versus TAS-102 Efficacy and Safety in Chemorefractory Metastatic Colorectal Cancer (mCRC) Patients: A Multi-institution Real Life Clinical Data
2021-09-0119
OAAI